Dr William Edward Hopkins, MD | |
111 Colchester Ave, Cardiology Unit, Mcclure 1 (mchv Campus), Burlington, VT 05401-1473 | |
(802) 847-3655 | |
(802) 847-8818 |
Full Name | Dr William Edward Hopkins |
---|---|
Gender | Male |
Speciality | Cardiovascular Disease (cardiology) |
Experience | 39 Years |
Location | 111 Colchester Ave, Burlington, Vermont |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1770685638 | NPI | - | NPPES |
01566247 | Medicaid | NY | |
0VN1148 | Medicaid | VT |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RC0000X | Internal Medicine - Cardiovascular Disease | 420009096 (Vermont) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Univ. Of Vermont - Fletcher Allen Health Care | Burlington, VT | Hospital |
Champlain Valley Physicians Hospital Medical Ctr | Plattsburgh, NY | Hospital |
Northwestern Medical Center Inc | Saint albans, VT | Hospital |
Copley Hospital | Morrisville, VT | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
University Of Vermont Medical Center Inc | 3779491071 | 994 |
Champlain Valley Physicians Hospital Medical Center | 2769396878 | 233 |
News Archive
A team of researchers from the National University of Singapore has uncovered the mystery behind the potent parasite-killing effect of artemisinin, a drug that is considered to be the last line of defence against malaria. Given the emergence of artemisinin resistance, these findings could potentially lead to the design of new treatments against drug-resistant parasites.
In African Americans with kidney disease related to hypertension (high blood pressure), a common gene variant is associated with a sharply increased risk of progressive kidney disease, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition. End Stage Renal Disease (ESRD) associated with hypertension occurs in the African American population at a rate 13.1 times greater than that of their white counterparts.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, is pleased to announce newly acquiring The Ocular Surface, a peer-reviewed journal focusing on the external eye and vision. As per January 2012 Elsevier will continue the publication of the quarterly journal.
Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.
› Verified 8 days ago
Entity Name | University Of Vermont Medical Center Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1659309615 PECOS PAC ID: 3779491071 Enrollment ID: O20040406001047 |
News Archive
A team of researchers from the National University of Singapore has uncovered the mystery behind the potent parasite-killing effect of artemisinin, a drug that is considered to be the last line of defence against malaria. Given the emergence of artemisinin resistance, these findings could potentially lead to the design of new treatments against drug-resistant parasites.
In African Americans with kidney disease related to hypertension (high blood pressure), a common gene variant is associated with a sharply increased risk of progressive kidney disease, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition. End Stage Renal Disease (ESRD) associated with hypertension occurs in the African American population at a rate 13.1 times greater than that of their white counterparts.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, is pleased to announce newly acquiring The Ocular Surface, a peer-reviewed journal focusing on the external eye and vision. As per January 2012 Elsevier will continue the publication of the quarterly journal.
Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Dr William Edward Hopkins, MD 111 Colchester Ave, Cardiology Unit, Mcclure 1 (mchv Campus), Burlington, VT 05401-1473 Ph: (802) 847-3655 | Dr William Edward Hopkins, MD 111 Colchester Ave, Cardiology Unit, Mcclure 1 (mchv Campus), Burlington, VT 05401-1473 Ph: (802) 847-3655 |
News Archive
A team of researchers from the National University of Singapore has uncovered the mystery behind the potent parasite-killing effect of artemisinin, a drug that is considered to be the last line of defence against malaria. Given the emergence of artemisinin resistance, these findings could potentially lead to the design of new treatments against drug-resistant parasites.
In African Americans with kidney disease related to hypertension (high blood pressure), a common gene variant is associated with a sharply increased risk of progressive kidney disease, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition. End Stage Renal Disease (ESRD) associated with hypertension occurs in the African American population at a rate 13.1 times greater than that of their white counterparts.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, is pleased to announce newly acquiring The Ocular Surface, a peer-reviewed journal focusing on the external eye and vision. As per January 2012 Elsevier will continue the publication of the quarterly journal.
Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.
› Verified 8 days ago
Nadia Ghallab, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 | |
Beach Conger, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 617 Riverside Ave, Burlington, VT 05401 Phone: 802-864-6309 Fax: 802-860-4313 | |
Dr. Christopher Dwight Huston, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-2264 | |
Beth Diane Kirkpatrick, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Fletcher Allen Health Care, Burlington, VT 05401 Phone: 802-847-4594 | |
Dr. Richard Frank Branda, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1 S. Prospect St, Burlington, VT 05401 Phone: 802-847-3827 Fax: 802-847-3510 | |
Lauren Suggs, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 | |
Magdalena Anna Zeglin, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 |